Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With:

  • Market Updates

    Implantable cardioverter defibrillator (ICD) implantation may contribute to a lower incidence of ventricular fibrillation (VF)-related out-of-hospital cardiac arrest treated by emergency medical services (EMS), according to a study published in the September issue of Heart Rhythm, a journal of the Heart Rhythm Society (formerly NASPE; Natick, Massachusetts).
  • Personnel File

    Abiomed (Danvers, Massachusetts) named Frank Menzler general manager for Abiomed BV, the company's European division. Menzler most recently was marketing manager for cardiac surgery for Guidant Europe and was a co-founder of Impella Cardiotechnik AG, a developer of minimally invasive blood pumps.
  • Product Pipeline

    Guidant (Indianapolis) said that the FDA has approved an expanded indication for the companys portfolio of cardiac resynchronization therapy defibrillators (CRT-D).
  • Trends in management of heart failure, arrhythmia in Europe

    Congestive heart failure (CHF) is a major and growing worldwide public health problem that is creating demands for a wide range of diagnostic, therapeutic and patient-monitoring technologies in Europe and most other developed regions.
  • Sessions eye diabetes’ impact on heart patients

    Several sessions held during last months congress of the European Society of Cardiology (ESC; Sophia Antipolis, France) in Munich, Germany, focused on the diabetic state of patients with coronary artery disease.
  • GE Healthcare calls its Vivid i ‘the virtual stethoscope of future’

    GE Healthcare (Waukesha, Wisconsin) has unveiled what it touted as the visual stethoscope of the future, a new, miniaturized cardiovascular ultrasound system it said was so small and lightweight that it will transform the way doctors see and treat heart disease.
  • Abbott enrolls first patient in study of its ZoMaxx DES

    The Abbott Vascular Devices (Redwood City, California) division of Abbott Laboratories (Abbott Park, Illinois) reported in mid-September that it had enrolled the first patient in its ZOMAXX I drug-eluting coronary stent clinical trial. ZOMAXX I is a 400-patient, randomized clinical trial that will be conducted in more than 30 centers in Europe, Australia and New Zealand.
  • FDA clears Philips’ HeartStart defibrillator for over-the-counter sales

    The FDA has granted clearance to a product that may shock some consumers literally. Philips Medical Systems (Bothell, Washington) got the nod from the FDA in mid-September to market its HeartStart Home Defibrillator over the counter for the treatment of sudden cardiac arrest (SCA), the first such clearance in the U.S.
  • Pediatric Headaches: Distinguishing the Common from the Serious

    Although headache is a common symptom in children and adolescents, only a very small percentage of patients present to the emergency department for evaluation of this complaint. The majority of these headaches are benign and are either primary, such as migraine or tension-type headaches, or secondary to a viral etiology. Parents and children themselves are most concerned about the possibility of a brain tumor, whereas ED physicians are also on the alert for carbon monoxide toxicity, subarachnoid hemorrhage, meningitis, and increased intracranial pressure. The authors review the causes, diagnostic testing, and treatment of the common headache, as well as some unusual causes of non-traumatic headache.
  • Full October 2004 Issue in PDF